Literature DB >> 20795889

Quetiapine: novel uses in the treatment of depressive and anxiety disorders.

Arun V Ravindran1, Abdullah Al-Subaie, Gebrehiwot Abraham.   

Abstract

IMPORTANCE OF THE FIELD: Quetiapine, an atypical antipsychotic, has been approved for the treatment of schizophrenia, acute mania, bipolar depression and unipolar major depression. However, it is often used (off-label) to treat other depressive disorders and anxiety disorders in children and adults. AREAS COVERED IN THIS REVIEW: This article reviews the evidence for the safety and efficacy of quetiapine in these populations, as both monotherapy and augmentation to other psychotropics. WHAT THE READER WILL GAIN: This article provides an in-depth review of the published literature on the topic and also provides recommendations for use. TAKE HOME MESSAGE: There is strong evidence to support the use of quetiapine in major depressive and generalized anxiety disorders, and preliminary support for treatment-resistant and psychotic depression. There is reasonable evidence of its benefits as an augmenting agent in obsessive-compulsive disorder, while data in other anxiety disorders are limited but promising. While long-term tolerability data are limited, quetiapine appears well tolerated in the short-term. Further randomized controlled trials are needed to confirm the efficacy and tolerability of quetiapine, both short- and long-term, in many of these conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20795889     DOI: 10.1517/13543784.2010.515586

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  7 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013.

Authors:  Henry C Ndukwe; June M Tordoff; Ting Wang; Prasad S Nishtala
Journal:  Drugs Aging       Date:  2014-10       Impact factor: 3.923

3.  Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys.

Authors:  Robert E Brutcher; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

4.  Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys.

Authors:  Robert E Brutcher; Susan H Nader; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2015-12-07       Impact factor: 4.030

5.  Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project.

Authors:  Elaine Stephanie Chow; Azadeh Zangeneh-Kazemi; Olabode Akintan; Elizabeth Chow-Tung; Alan Eppel; Khrista Boylan
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2017-07-01

6.  Who prescribes quetiapine in Denmark?

Authors:  Mikkel Højlund; Lotte Rasmussen; Morten Olesen; Trine Munk-Olsen; Anton Pottegård
Journal:  Br J Clin Pharmacol       Date:  2022-05-19       Impact factor: 3.716

7.  Recurrent priapism from therapeutic quetiapine.

Authors:  Omeed Saghafi; Amanda Kao; Jeffrey Druck
Journal:  West J Emerg Med       Date:  2014-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.